Amgen Inc (AMGN) operating KPIs
AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$466.01+5.28 (+1.15%)
Close on Oct 30, 2026Market cap $251.94BP/E 28.9Yield 2.07%
Amgen restructuring & Asset Impairment Expense (legacy) ($M) ($M)
Form 10-K Restructuring Note (XBRL)
Latest, Q4 2015
-52
Period ended Dec 31, 2015
Change on a year earlier
–
History
4 quarters
Since Q1 2015
Sources
2
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Restructuring & Asset Impairment Expense (legacy) ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q4 2015 | Dec 31, 2015 | -52 | – | Form 10-K (filed 2018-02-13) ↗ |
| Q3 2015 | Sep 30, 2015 | 11 | – | 10-Q FY2015 (XBRL) ↗ |
| Q2 2015 | Jun 30, 2015 | 63 | – | 10-Q FY2015 (XBRL) ↗ |
| Q1 2015 | Mar 31, 2015 | 92 | – | 10-Q FY2015 (XBRL) ↗ |
Cite this data
StockData. (2026). Amgen Restructuring & Asset Impairment Expense (legacy) ($M) ($M), quarterly Q1 2015–Q4 2015 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/restruct_impair_exp
See every metric in the Amgen KPI table. Data updated Oct 28, 2026.